Entos Pharmaceuticals Inc.
$10,000,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- September 1, 2020 – August 31, 2021
- Reference
- nrc-cnrc:172-2020-2021-Q2-956891
Published purpose
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine candidate through Phase 1 clinical trials to establish its safety and immunogenicity in healthy adults.
In plain English AI-generated
Funding supports Entos Pharmaceuticals to advance its COVID-19 DNA vaccine candidate through Phase 1 clinical trials in Canada, testing safety and immune response in healthy adults.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.